Advertisement

Topics

Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer

2016-09-21 20:23:22 | BioPortfolio

Summary

The purpose of this study is to investigate whether tocotrienol can improve the effect and reduce the side effects of standard chemotherapy before operation for breast cancer.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Breast Cancer

Intervention

Epirubicin 90 mg/m2 iv, Cyclophosphamide 600 mg/m2 iv, Docetaxel 100 mg/m2 iv OR paclitaxel 80 mg/m2 iv, Trastuzumab 8 mg/kg iv saturation, then 6 mg/kg iv (HER2 positive patients only), Pertuzumab 840 mg iv saturation, then 420 mg iv (selected HER2 posit

Location

Vejle hospital, Department of Oncology
Vejle
Denmark

Status

Recruiting

Source

Vejle Hospital

Results (where available)

View Results

Links

Published on BioPortfolio: 2016-09-21T20:23:22-0400

Clinical Trials [2433 Associated Clinical Trials listed on BioPortfolio]

Epirubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab in Treating Women With HER2-Positive Stage III or Stage IV Breast Cancer

RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stop...

Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

Phase II randomized multicenter Trial to compare Epirubicine and Cyclophosphamide plus Docetaxel and Trastuzumab with Epirubicine and Cyclophosphamide plus Docetaxel and Lapatinib for pati...

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

The main purpose is to learn if adding bevacizumab to standard chemotherapy and trastuzumab to treat HER2-positive breast cancer will affect heart function. This study will evaluate: - ...

A Study to Compare Subcutaneous Versus Intravenous Administration of Herceptin (Trastuzumab) in Women With HER2-Positive Early Breast Cancer

In this open-label multicenter trial patients with operable or locally advanced breast cancer will be randomized to pre-operative treatment with 8 cycles of che motherapy (docetaxel follow...

A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer.

This multicenter, non-randomized, open-label, phase II study is designed to evaluate the safety and efficacy of Perjeta in combination with Herceptin and anthracycline-based chemotherapy a...

PubMed Articles [1370 Associated PubMed Articles listed on BioPortfolio]

Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer.

The standard primary systemic therapy for human epidermal growth factor receptor 2-positive (HER2+) breast cancer is anthracyclines and/or taxanes combined with trastuzumab, which demonstrates a high ...

A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.

Akt plays a key role in the aggressive pathogenesis of HER2+ malignancies, suggesting that Akt-inhibitors may be of therapeutic value in the treatment of HER2+ tumors. Preclinical studies demonstrate ...

Association between HER2 status and response to neoadjuvant anthracycline followed by paclitaxel plus carboplatin chemotherapy without trastuzumab in breast cancer.

We recently showed HER2-positive breast cancers are less likely to respond to neoadjuvant anthracycline chemotherapy. Here, we investigated whether HER2-positive breast cancers responded to sequential...

HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.

Adjuvant therapy comprising the HER2 receptor antagonist trastuzumab is associated with a significant improvement in disease-free and overall survival as compared to chemotherapy alone in localized HE...

Outcomes of re-treatment with first-line Trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant Trastuzumab: A prospective multicenter study.

Trastuzumab is the backbone of HER2-positive early breast cancer (eBC) and metastatic breast cancer (mBC) treatment, but limited data exist as to re-treatment in relapsed patients. In this prospective...

Medical and Biotech [MESH] Definitions

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.

A method for extinguishing anxiety by a saturation exposure to the feared stimulus situation or its substitute.

A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.

A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.

More From BioPortfolio on "Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer"

Quick Search
Advertisement
 

Relevant Topics

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...


Searches Linking to this Trial